[2006alum]

I haven't noticed many stating positive results related to Chloroquine, but one did come out this week.  I'm not in position to judge its quality:  https://www.medrxiv.org/content/10.1101/...20057539v1  "none of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%) by propensity score matching."

That report also did indicate that those with hypertension using ACE Inhibitors & ARB therapies had better outcomes than thosse that used other drugs.

Hmm. Quoting the entirety of the findings section of this paper:

Findings:  In  this  retrospective,  observational  cohort  study involving  564  patients  with  confirmed COVID-19,  hypertension  was  an  independent  risk  factor  for  progression  to  severe  pneumonia irrespective  of  age  and  those  on  angiotensin-converting  enzyme  inhibitor  (ACEI)  or  angiotensin receptor  blocker  (ARB)  therapy  were  less  likely  to  develop  severe  COVID-19  pneumonia,  while nonspecific antivirals or chloroquine did not have significant impact on clinical progression.

Am I misunderstanding what this would constitute "positive results related to chloroquine"?

[2006alum]

I haven't noticed many stating positive results related to Chloroquine, but one did come out this week.  I'm not in position to judge its quality:  https://www.medrxiv.org/content/10.1101/...20057539v1  "none of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%) by propensity score matching."

That report also did indicate that those with hypertension using ACE Inhibitors & ARB therapies had better outcomes than thosse that used other drugs.

Hmm. Quoting the entirety of the findings section of this paper:

Findings:  In  this  retrospective,  observational  cohort  study involving  564  patients  with  confirmed COVID-19,  hypertension  was  an  independent  risk  factor  for  progression  to  severe  pneumonia irrespective  of  age  and  those  on  angiotensin-converting  enzyme  inhibitor  (ACEI)  or  angiotensin receptor  blocker  (ARB)  therapy  were  less  likely  to  develop  severe  COVID-19  pneumonia,  while nonspecific antivirals or chloroquine did not have significant impact on clinical progression.

Am I misunderstanding what this would constitute "positive results related to chloroquine"?